Dr. Daniel A. Salerno, Director of Critical Care Services in the Respiratory ICU at Temple University Hospital and Professor of Clinical Thoracic Medicine & Surgery at the Lewis Katz School of Medicine at Temple University, has provided his perspective to Medscape regarding new research findings on brensocatib. The study was presented at the American College of Chest Physicians (CHEST) Annual Meeting in Chicago.
The research focused on the impact of brensocatib, a drug recently approved by the U.S. Food and Drug Administration for use in patients with noncystic fibrosis bronchiectasis, on structural lung disease. Dr. Salerno clarified that he did not participate in conducting this study.
